These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26495019)

  • 1. Chinese Herbal Medicines Might Improve the Long-Term Clinical Outcomes in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: Results of a Decision-Analytic Markov Model.
    Wang SL; Wang CL; Wang PL; Xu H; Chen KJ; Shi DZ
    Evid Based Complement Alternat Med; 2015; 2015():639267. PubMed ID: 26495019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial.
    Wang PL; Zhang L; Wang SL; Yang QN; Gao ZY; Du JP; Zhang DW; Fu CG; Gu F; Xu H; Li LZ; Wang CL; Shi DZ
    Chin J Integr Med; 2017 Oct; 23(10):740-746. PubMed ID: 27778264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study.
    Wang SL; Wang CL; Wang PL; Xu H; Liu HY; Du JP; Zhang DW; Gao ZY; Zhang L; Fu CG; Lü SZ; You SJ; Ge JB; Li TC; Wang X; Yang GL; Liu HX; Mao JY; Li RJ; Chen LD; Lu S; Shi DZ; Chen KJ
    Evid Based Complement Alternat Med; 2013; 2013():741518. PubMed ID: 23935679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention.
    Zhang DW; Wang SL; Wang PL; Du JP; Gao ZY; Wang CL; Xu H; Shi DZ
    J Ethnopharmacol; 2020 Feb; 248():112354. PubMed ID: 31689480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
    Zhang L; Lin Z; Yin H; Liu J; Xuan J
    Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Assessing Chinese herbal medicines for benefiting qi and activating blood circulation in treating unstable angina based on Markov model: a long-term clinical effectiveness exploration].
    Wang CL; Shi DZ; Wang Q; Wang SL
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Apr; 34(4):406-11. PubMed ID: 24812893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention.
    Zheng GH; Liu JP; Wang NS; Chen HY; Chu JF
    Evid Based Complement Alternat Med; 2012; 2012():253409. PubMed ID: 22454659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.
    Heeg BM; Peters RJ; Botteman M; van Hout BA
    Pharmacoeconomics; 2007; 25(9):769-82. PubMed ID: 17803335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
    Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
    Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
    Davies A; Bakhai A; Schmitt C; Barrett A; Graham-Clarke P; Sculpher M
    J Med Econ; 2013; 16(4):510-21. PubMed ID: 23339464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
    Schwenkglenks M; Brazier JE; Szucs TD; Fox KA
    Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
    Ross Terres JA; Lozano-Ortega G; Kendall R; Sculpher MJ
    BMC Cardiovasc Disord; 2015 Dec; 15():180. PubMed ID: 26715178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
    Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
    Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of Chinese Herbs for Supplementing Qi and Activating Blood Circulation on Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus after Percutaneous Coronary Intervention: a Clinical Observation].
    Du JP; Wang CL; Wang PL; Wang SL; Gao ZY; Zhang DW; Xu H; Shi DZ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 May; 35(5):563-7. PubMed ID: 26159020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation).
    Fearon WF; Nishi T; De Bruyne B; Boothroyd DB; Barbato E; Tonino P; Jüni P; Pijls NHJ; Hlatky MA;
    Circulation; 2018 Jan; 137(5):480-487. PubMed ID: 29097450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.